Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure

Health Affairs

Volumn 35, Issue 5, 2016, Pages 805-812

  Bennette, Caroline S ^a   Richards, Catherine ^b   Sullivan, Sean D ^a   Ramsey, Scott D ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Aetion Inc   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER THERAPY; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; OFF LABEL DRUG USE; COMMERCIAL PHENOMENA; ECONOMIC ASPECT; ECONOMICS; HEALTH INSURANCE; ORAL DRUG ADMINISTRATION; TRENDS; UNITED STATES;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; COMMERCE; DRUG COSTS; ECONOMIC COMPETITION; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84969199633     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2015.1145     Document Type: Article

References (38)

1. Martell RE, Sermer D, Getz K, Kaitin KI. Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration. Oncologist. 2013; 18(1):104-11.
2. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626-33.
3. Guy GP Jr, Yabroff KR, Ekwueme DU, Smith AW, Dowling EC, Rechis R, et al. Estimating the health and economic burden of cancer among those diagnosed as adolescents and young adults. Health Aff (Millwood). 2014;33(6):1024-31.
4. Guy GP Jr, Ekwueme DU, Yabroff KR, Dowling EC, Li C, Rodriguez JL, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013; 31(30):3749-57.
5. Kent EE, Forsythe LP, Yabroff KR, Weaver KE, de Moor JS, Rodriguez JL, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119(20):3710-7.
6. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: fromthe perspective of a large group of CML experts. Blood. 2013;121(22):4439-42.
7. Pollack A. Doctors denounce cancer drug prices of $100,000 a year. New York Times. 2013 Apr 25.
8. Stahl L. The cost of cancer drugs. 60 Minutes [serial on the Internet]. 2014 Oct 5 [cited 2016 Mar 16]. Available from: http://www.cbsnews .com/news/the-cost-of-cancerdrugs/
9. Bach PB.Why drugs cost so much. New York Times. 2015 Jan 14.
10. Danzon PM, Taylor E. Drug pricing and value in oncology. Oncologist. 2010;15(Suppl 1):24-31.
11. Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012; 87(10):935-43.
12. Ramsey SD. How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs. Health Aff (Millwood). 2015;34(4):571-5.
13. Temple R. Letter to Robert A. Miranda, associate director, drug regulatory affairs, Novartis Pharmaceuticals Corporation [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2016 Mar 16]. Available from: http://www.access data.fda.gov/drugsatfda_docs/ appletter/2001/21335ltr.pdf
14. Pazdur R. Letter to Robert A. Miranda, associate director, drug regulatory affairs, Novartis Pharmaceuticals Corporation [Internet]. Rockville (MD): Food and Drug Administration; [cited 2016 Mar 16]. Available from: http://www.access data.fda.gov/drugsatfda_docs/ appletter/2002/21335s001ltr.pdf
15. Farrell A. Letter to Joseph Quintavalla, senior regulatory manager, drug regulatory affairs, Novartis Pharmaceuticals Corporation [Internet]. Rockville (MD): Food and Drug Aministration; 2006 Sep 27 [cited 2016 Mar 16]. Available from: http://www.accessdata.fda .gov/drugsatfda_docs/appletter/2006/021588s016ltr.pdf
16. To access the Appendix, click on the Appendix link in the box to the right of the article online.
17. Abernethy AP, Raman G, Balk EM, Hammond JM, Orlando LA,Wheeler JL, et al. Systematic review: reliability of compendia methods for offlabel oncology indications. Ann Intern Med. 2009;150(5):336-43.
18. American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 200; 24(19):3206-8.
19. Kalis JA, Pence SJ, Mancini RS, Zuckerman DS, Ineck JR. Prevalence of off-label use of oral oncolytics at a community cancer center. J Oncol Pract. 2015;11(2):e139-43.
20. Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB. Prevalence of off-label use and spending in 2010 among patentprotected chemotherapies in a population- based cohort of medical oncologists. J Clin Oncol. 2013; 31(9):1134-9.
21. Food and Drug Administration. FDA online label repository [Internet]. Silver Spring (MD): FDA; [cited 2016 Mar 17]. Available from: http:// labels.fda.gov/
22. Truven Health Analytics. Compendia transparency [Internet]. Greenwich Village (CO): Truven; c 2016 [cited 2016 Mar 16]. Available from:http://micromedex.com/compendia
23. National Cancer Institute. Drugs approved for different types of cancer [Internet]. Bethesda (MD): NCI; [updated 2015 Jan 16; cited 2016 Mar 17]. Available from: http:// www.cancer.gov/cancertopics/drug info/drug-page-index
24. Food and Drug Administration. Drugs-FDA database [Internet]. Silver Spring (MD): FDA; [last updated 2014 Oct 23; cited 2016 Mar 17]. Available from: http:// www.fda.gov/Drugs/InformationOn Drugs/ucm135821.htm
25. Driscoll JC, Kraay AC. Consistent covariance matrix estimation with spatially dependent panel data. Rev Econ Stat. 1998;80(4):549-60.
26. Trish E, Joyce G, Goldman DP. Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11. Health Aff (Millwood). 2014;33(11):2018-24.
27. Shih YC, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol. 2015;33(19):2190-6.
28. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139-62.
29. Outterson K, Kesselheim AS. How Medicare could get better prices on prescription drugs. Health Aff (Millwood). 2009;28(5):w832-41. DOI: 10.1377/hlthaff.28.5.w832.
30. Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, et al. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm. 2015;21(4):269-75.
31. Robinson JC, Howell S. Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use. Health Aff (Millwood). 2014;33(10):1745-50.
32. Schnipper LE, Davidson NE,Wollins DS, Tyne C, Blayney DW, Blum D, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563-77.
33. Memorial Sloan Kettering Cancer Center. Evidence Based Drug Pricing Project [home page on the Internet]. New York (NY): The Center; [cited 2016 Mar 17]. Available from: http:// www.drugabacus.org/
34. Neumann PJ, Cohen JT. Measuring the value of prescription drugs. N Engl J Med. 2015;373(27):2595-7.
35. Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014; 312(16):1629-30.
36. Loftus P. New push ties cost of drugs to how well they work. Wall Street Journal. 2015 May 26.
37. Conti RM, Berndt ER. Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007 [Internet]. Cambridge (MA): National Bureau of Economic Research; 2014 Mar [cited 2016 Mar 17]. (NBER Working Paper No. 20016). Available from: http://www.nber .org/papers/w20016.pdf
38. Conti RM, Padula WV, Larson RA. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol. 2015; 94(Suppl 2):S249-57.